Tesamorelin was engineered with a trans-3-hexenoic acid modification that protects it from DPP-IV degradation, extending its half-life from the ~7 minutes of native GHRH to approximately 26 minutes
Plasma GHK-Cu concentrations decline with age, from approximately 200 ng/mL at age 20 to under 80 ng/mL by age 60, correlating with reduced skin repair capacity
What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
It helps extend the product story beyond basic brightening
Add your review 0 stars based on 0 reviews SPEKTRUM Add to wishlist / Add to compare / Print